G rowth of the heart in the young and maturing animals is primarily the result of hypertrophy of a preexisting, fixed number of cardiomyocytes rather than cellular proliferation.' The underlying mechanisms of such cardiac hypertrophy remains obscure, but several growth factors may be involved. Growth factors, such as transforming growth factor-1 and basic fibroblast growth factor, have been shown to induce cardiomyocyte hypertrophy in vitro. 2, 3 Insulinlike growth factor-I (IGF-I),4 or somatomedin C, is a fundamental growth factor essential for the regulation of cell proliferation and differentiation. This basic peptide with 70-amino-acid residues is the major mediator through which growth hormone exerts its growth-promoting effects in a variety of tissues. Recently, the presence of IGF-I receptors on rat myocardium has been demonstrated, suggesting its potential role as one of the growth factors for the development of neonatal rat cardiomyocytes.5 It should be also noted that cardiac hypertrophy is commonly observed in adult acromegalic patients, in whom excessive secretion of growth hormone from pituitary adenoma is associated with elevated circulating IGF-I levels.6 Therefore, the cardiac abnormalities observed in acromegalic patients may result from the action of excessive circulating IGF-I on the heart. However, the neutralize their biological actions. IGFBP-3, an acidlabile glycoprotein with a molecular weight of 53,000,7 is a major carrier protein for both IGF-I and IGF-II in the serum (see the review of Rutanen and Pekonen8). Although a number of studies have shown that IGFBPs modify biological effects of IGFs on a variety of mammalian cells,9-11 the physiological relevance of these binding proteins in the heart remains unclear.
In the present study, we demonstrate for the first time that IGF-I induces hypertrophy with concomitant increases in the transcripts of muscle-specific genes and that the hypertrophic effect of IGF-I on rat cardiomyocytes is completely blocked by IGFBP-3. 
Results
Cardiomyocytes after treatment with IGF-I (10-`M) for 48 hours apparently became enlarged ( Figure 1) ; cell surface area of cardiomyocytes treated with IGF-I (1,319±51 gm2, n=50) was significantly (p<0.01) greater than that of nontreated cells (664±31 ,um2, n=50), whereas the number of cardiomyocytes was unchanged.
IGF-I (10-7 M) increased mRNA levels for MLC-2, troponin I, and a-actin as early as 60 minutes and continued to 24 hours. The maximum responses of expression for three muscle-specific genes were induced after 6 hours, whereas IGF-I did not affect mRNA level for pyruvate kinase, using as a control (Figure 2A) . Furthermore, Northern blot analysis using cDNAs for 3' untranslated region of skeletal and cardiac a-actin as probes revealed that skeletal a-actin mRNA level was increased by IGF-I treatment (10-`M), whereas cardiac a-actin mRNA level was unchanged ( Figure 2B ). Transcripts for MLC-2 and troponin I were unaffected by growth hormone treatment (10-`M) for 6 and 24 hours ( Figure 3) .
As shown in Figure 4 , IGF-I stimulated [3H]leucine uptake in a dose-dependent manner Competitive binding study using`2I-IGF-I as a radioligand revealed that unlabeled IGF-I and IGF-II equivalently inhibited the binding of '`I-IGF-I to rat cardiomyocytes with an approximate dose for the halfmaximum inhibition (IC50) of 2.5-5x 10-8 M, whereas insulin was ineffective ( Figure SA) . By contrast, competitive binding study using`PI-IGF-II as a radioligand revealed that unlabeled IGF-II competitively inhibited the binding of`PI-IGF-II with an approximate IC50 of Concentrations of immunoreactive IGF-I in culture media after treatment with or without growth hormone (10-`M) for 24 hours were undetectable (<4x 10`M).
Discussion
The present study has demonstrated for the first time that IGF-I has a direct hypertrophic effect on cultured rat cardiomyocytes with concomitant increases in the transcripts of muscle-specific genes (MLC-2, troponin I, and skeletal a-actin) and that IGFBP-3 has an inhibitory effect on the IGF-I-induced cardiac hypertrophy in vitro.
Cultured cardiomyocytes from neonatal rats have proven to be useful for in vitro studies of myocardial growth and metabolism. It has been shown that growth of cardiomyocytes is primarily due to hypertrophy rather than hyperplasia.1 20 ration in Ara-C-treated cultures was more potent than that in NMCs suggest that the protein synthesis stimulated by IGF-I in the present culture system reflected the preferential IGF-I activity on cardiomyocytes rather than on NMCs. There was an apparent discrepancy between the approximate value of EC50 for stimulating protein synthesis (-5 x 10-10 M) and that of IC50 for the receptor binding (-4x 108 M). Such discrepancy may be explained by the small fraction of IGF-I receptors essential for protein synthesis and the abundant spare receptors in cardiomyocytes. Cardiovascular abnormalities such as hypertension and cardiac hypertrophy are common in the patients with acromegaly and giantism, in whom pituitary ademona secretes large amounts of growth hormone with a consequence of elevated circulating IGF-I levels. Based on the in vivo experimental observations that ventricular weights, external cardiac dimensions, and myocardial fiber diameters were increased in the rats with implanted growth hormone-secreting tumor,25 the cardiac enlargement observed in acromegalic patients may result from direct action of growth hormone or indirect action mediated by IGF-I on the heart. Therefore, the present results might offer the possible implication of IGF-I in the pathogenesis of cardiac hypertrophy associated with acromegaly and giantism. However, we must be cautious in interpreting that the phenomenon observed in vitro mirrors the clinical entity because of the following reasons. First, the cultured cells are neonatal cardiomyocytes, whereas the clinical entity develops in mature hearts. Second, the changes in gene expression described in the present study generally are those associated with pressure-overload types of cardiac hypertrophy, whereas the patterns of gene expression seen with excess growth hormone in the intact heart are somewhat different; specifically marked increases of a-myosin heavy chain mRNA are not seen.26 Third, the hemodynamic stress associated with the clinical disease have not yet been duplicated in culture. Therefore, the significance of the "reexpression" of skeletal specific isoforms of a-actin by IGF-I treatment is that this is the only in vitro correlate we have for the changes seen with pressure-load hypertrophy in vivo, and this may be a marker of a pathological stress perceived by the cardiac myocytes.
Growth hormone stimulates growth of a variety of mammalian organs through its stimulatory effect on synthesis of IGF-I, which can act via endocrine, autocrine or paracrine mechanisms (see the review of Thorner and Vance27). Human growth hormone has been shown to increase mRNA levels and secretion of IGF-I in the hypophysectomized rat liver,2829 and it generally is believed that the liver is the main organ for production of IGF-I, which then acts on a variety of target organs as a circulating growth factor. In the present study, however, growth hormone did not increase muscle-specific mRNA levels or stimulate protein synthesis in rat cardiomyocytes, suggesting that growth hormone per se has no direct hypertrophic effect on cardiomyocytes. Furthermore, our study showed that immunoreactive IGF-I was undetectable in the culture media from both control and growth hormone-treated cardiomyocytes, suggesting that growth hormone has no or little direct effect on IGF-I production by cardiomyocytes.
IGFBPs have been found to inhibit various in vitro actions of IGF-I, including stimulation of glucose transport by adipocytes,30 sulfate incorporation by chondrocytes,31 amino acid uptake by choriocarcinoma cells," 
